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Abstract 
Background: Germline mutations within DNA repair genes are implicated in susceptibility to 
multiple forms of cancer. For prostate cancer (PrCa), rare mutations in BRCA2 and BRCA1 
give rise to moderately elevated risk, whilst two of approximately 100 common, low 
penetrance PrCa susceptibility variants identified so far by genome-wide association studies 
implicate RAD51B and RAD23B. 
Methods: Genotype data from the iCOGS array was imputed to the 1000 genomes phase 3 
reference panel for 21,780 PrCa cases and 21,727 controls from the PRACTICAL consortium. 
We subsequently performed single variant, gene and pathway level analyses using 81,303 
SNPs within 20Kb of a panel of 179 DNA repair genes.  
Results: Single SNP analyses identified only the previously reported association with 
RAD51B. Gene-level analyses using the SKAT-C test identified a significant association with 
PrCa for MSH5. Pathway level analyses suggested a possible role for the translesion 
synthesis pathway in PrCa risk and Homologous recombination/Fanconi Anemia pathway for 
PrCa aggressiveness, even though after adjustment for multiple testing these did not remain 
significant. 
Conclusion: MSH5 is a novel candidate gene warranting additional follow-up as a 
prospective PrCa risk locus. MSH5 has previously been reported as a pleiotropic 
susceptibility locus for lung, colorectal and serous ovarian cancers. 
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Introduction 
Prostate Cancer (PrCa) is the most frequently diagnosed cancer among men in developed 
countries and despite high survival rates also one of the highest for mortality (Cancer 
Research UK, 2014; Quaresma et al, 2015). However, as the majority of prostate neoplasms 
develop extremely slowly, many do not require clinical intervention; which coupled with the 
low specificity of the prostate specific antigen (PSA) test for clinically relevant forms of the 
disease could potentially lead to considerable over-diagnosis and overtreatment of patients 
for relatively modest reductions in mortality (Ilic et al, 2013). In conjunction with the 
establishment of improved biomarkers for lethal PrCa, the identification of individuals at 
greater risk of developing prostate tumours that require clinical intervention would also 
help inform more targeted and appropriate application of treatment. The heritability of 
PrCa is believed to be the highest of all the common forms of cancer (Hjelmborg et al, 2014). 
This is consistent with observations from genome-wide association studies (GWAS), which 
have to date identified more than 100 low penetrance susceptibility variants for PrCa, two 
of which implicate the DNA repair genes RAD51B and RAD23B (Al Olama et al, 2014; Amin Al 
Olama et al, 2015; Eeles et al, 2014; Xu et al, 2012). In addition, rare germline mutations in a 
small number of genes have been reported, with varying degrees of evidence, as potentially 
conferring greater risks of PrCa, including the DNA repair genes ATM, BRCA1, BRCA2, BRIP1, 
CHEK2 and NBN (Dong et al, 2003; Kote-Jarai et al, 2009; Kote-Jarai et al, 2011; 
Leongamornlert et al, 2012; Leongamornlert et al, 2014; Robinson et al, 2015). Recently, 
increasing evidence has demonstrated that these germline DNA repair gene mutation 
carriers are at increased likelihood of experiencing advanced disease, metastatic spread and 
poorer survival outcome; yet these mutations also hold promise as potentially clinically 
actionable and responsive to targeted treatments (Castro et al, 2013; Cybulski et al, 2013; 
Leongamornlert et al, 2014; Robinson et al, 2015). In spite of these discoveries, the majority 
of the excess familial risk of PrCa still remains to be explained (Attard et al, 2015); with the 
contribution of DNA repair gene variants identified to date making them attractive 
candidates for further investigation. In this study, using data from the iCOGS project 
imputed to the 1000 Genomes Phase 3 reference panel, we have analysed a large panel of 
DNA repair gene variants for 21,780 PrCa cases and 21,727 controls of European ancestry 
from the PRACTICAL Consortium (Eeles et al, 2013). Analyses were performed at single 
variant, gene and pathway levels to maximise the power to detect putative associations 
with lower frequency variants or those with modest effect sizes. 
 
Results 
Using genotype data from the iCOGS study imputed to the 1000 genomes phase 3 reference 
panel we analysed 81,303 SNPs within a 20kb flanking region of 179 genes with a core 
function in DNA damage repair (Supplementary Table 1). Rare and uncommon variants 
represented a substantial proportion of the dataset, with 29,503 variants of MAF ≤1%, 
16,689 with MAF 1-5% and 35,111 with MAF >5% (Supplementary Figure 1a). Variants were 
categorised as SNPs, insertions and deletions, annotated using wANNOVAR (Chang & Wang, 
2012; Wang et al, 2010), and classified into five categories; coding, UTR, splice, intronic and 
intergenic. Variants available for this analysis were predominantly situated within non-
coding (intronic or intergenic) regions, with 3,943 variants annotated as coding, splice or 
UTR in total; whilst most were single base substitutions, with 3,914 insertions and 5,576 
deletions respectively. All of the insertion and deletion variants were imputed, with the vast 
majority located within non-coding regions (Supplementary Figure 1b-d, Supplementary 
Table 2). All analyses were adjusted for study population and the first eight principal 
components. For single variant level analyses the genome-wide significance threshold 
(P<5×10-8) was used to determine significantly associated variants, whereas for gene and 
pathway level analyses the significance threshold was defined according to the Bonferroni 
correction (Gene P<2.7×10-4, Pathway P<5.56×10-3). 
Single variant analysis for association of DNA repair gene variants with PrCa identified only 
the previously reported association with RAD51B at Chr14q24 (rs371311594, P = 1.29x10-10). 
Several other gene loci showed suggestive association peaks; however no other variants 
were within one order of magnitude of genome-wide significance (Figure 1, Supplementary 
Table 3). 
We observed evidence for modest inflation within our association data (λ = 1.105); 
nonetheless, departure from the null was apparent towards the extremity of the P-value 
distribution and this persisted to a more modest extent even after the RAD51B region was 
excluded (Supplementary Figure 2). We subsequently performed gene level association 
tests, in an attempt to ascertain whether additional putative PrCa risk signals might be 
present among the genes within which no individual variant achieved significance after 
adjustment for multiple testing, arising through a cumulative effect of several low MAF or 
low penetrance variants. We performed two gene level association tests using the SNP-set 
(Sequence) Kernel Association Test (SKAT); SKAT-C, which is optimised for combined testing 
of rare and common variants and SKAT-O, which attempts to maximise power for rare 
variant testing (Ionita-Laza et al, 2013; Lee et al, 2012). Gene-level analysis identified a novel 
significant association with the MSH5 gene using the SKAT-C test (Chr6p21; P = 1.68x10-4) 
(Figure 2, Supplementary Table 4). We used stepAIC and leave one out for SKAT to further 
interrogate the MSH5 data for the individual variants that best explain the signal. This test 
selected three variants at the MSH5 locus, rs61036903 (known as 6:31713892 within the 
reference panel) intronic within the gene and two variants 10kb downstream within an 
adjacent gene VWA7, rs805825 and rs185333600. These were all among the top ranking 
variants in the single SNP analysis (rs61036903: MAF = 0.14, OR 0.92, P = 8.06×10-5; 
rs805825: MAF = 0.45, OR 0.94, P = 4.05×10-5; rs185333600: MAF = 0.003, OR 1.57, P = 
6.83×10-4). 
We subsequently examined the iCOGS dataset at the pathway level under the SKAT test to 
supplement the gene level analyses. We again used the Bonferroni correction to define the 
significance threshold (Pathway P<5.56×10-3). No pathway achieved significance at this 
threshold, with suggestive associations under the SKAT-O test observed with the translesion 
synthesis pathway (P = 6.18×10-3) and mismatch repair pathway (P = 0.056).  
Variants within the coding sequence of DNA repair genes could be more likely to influence 
PrCa risk than those in non-coding regions. We therefore performed an additional SKAT test 
to assess whether the coding DNA repair gene variants available for this study, when 
collapsed as a single entity, could stratify case and control status. We observed a significant 
association when using the SKAT-C test (P = 0.003), which suggests that variants that affect 
the coding sequence of genes participating in DNA repair processes contribute to PrCa risk. 
We attempted to further elaborate upon this finding by analysing coding variation within 
each pathway separately. Despite relatively modest numbers of coding variants available 
within each pathway, we continued to observe suggestive associations under the SKAT-O 
test for the translesion synthesis pathway (P = 0.026) and mismatch repair pathway (P = 
0.055), in addition to the Homologous Recombination/Fanconi Anemia pathway under the 
SKAT-C test (P = 0.011).  
To complement the tests designed to identify potential PrCa susceptibility variants and 
genes, we also performed case-case analyses to investigate whether individual or 
cumulative germline DNA repair gene and pathway variants in the iCOGS imputed dataset 
correlated with phenotypic characteristics of more aggressive PrCa. This analysis was limited 
by lack of complete phenotypic data for all patients within the iCOGS sample set and low 
numbers of samples within individual phenotypic subgroups; therefore, we utilised two 
separate criteria to define aggressive and non-aggressive disease. For a stringent 
comparison of non-aggressive and aggressive PrCa, we analysed NCCN stage 1 patients 
against individuals with metastatic disease (M+) or nodal spread (N+) (395 NCCN1 vs. 1391 
M+/N+), whilst to maximise the numbers of samples available we also compared patients 
with Gleason Stage (GS) ≤6 disease against those with Gleason Stage ≥8 (9626 GS≤6 vs 2776 
GS≥8). No significant associations with aggressive PrCa were identified at either the variant 
or gene levels for either of the phenotypic criteria tested. (Supplementary Figure 3, 
Supplementary Table 5). When we examined PrCa aggressiveness at the pathway level, we 
observed associations at P < 0.05 for the Homologous Recombination/Fanconi Anemia 
(HR/FA) pathway under both tests for the GS ≤6 vs. GS ≥8 phenotype cohort (SKAT-C P = 
0.011, SKAT-O P = 0.040). This pathway was also the highest ranked for the NCCN1 vs. M+/N+ 
phenotype cohort under the SKAT-C test (P = 0.052). When these analyses were restricted 
to only coding variants, an association at P < 0.05 remained for the HR/FA pathway for the 
NCCN1 vs. M+/N+ cohort and the SKAT-O test (P = 0.021). These suggestive associations 
were not however significant after adjustment for multiple testing (Supplementary Table 5). 
 
Discussion 
DNA repair genes play a crucial role in the correction of damage to the genome of a cell and 
therefore their impairment can lead to carcinogenesis. Whilst these detrimental genetic 
alterations frequently originate within somatic cells during an individual’s lifetime, a number 
of rare, hereditary mutations within specific DNA repair genes have been identified that 
confer substantially increased risks to the individual of PrCa and other cancers. GWAS have 
also previously identified common, low penetrance variants in close proximity to the DNA 
repair genes RAD51B and RAD23B that contribute to PrCa susceptibility (Amin Al Olama et 
al, 2015; Eeles et al, 2013; Xu et al, 2012). However, even relatively well powered genetic 
association studies may have been limited in their ability to reliably interrogate variants 
with lower MAFs or associations with modest effect sizes; therefore additional risk variants 
that confer their functional effect though DNA repair genes may remain to be discovered. 
We have recently imputed PrCa data from the iCOGS study to the 1000 Genomes phase 3 
reference panel, thereby enhancing the capability to interrogate this dataset for untyped 
variants within tagged regions. In particular, a far greater number of lower MAF and 
insertion and deletion variants were available for analysis, although these are 
predominantly situated in non-coding regions. Imputation performance of lower MAF 
variants is improved by larger reference panel size and ethnic diversity and higher marker 
density on the genotyping array; however rare variants still regularly remain challenging to 
impute without an additional reference panel enriched for specific low frequency variants of 
known interest, and may also be more sensitive to differences in the imputation approach 
employed (Hoffmann & Witte, 2015). Our relatively large sample size provided good power 
to detect associations with PrCa for rare variants with greater effect sizes (e.g. for a variant 
at our 0.1% MAF cut-off with OR 2.5, we had 78% power) as well as common, low 
penetrance variants (e.g. for a variant with OR 1.1 and a MAF of 20%, power was 86%). We 
were however limited with respect to the detection of variants with the combination of 
both modest allele frequency and effect size. 
We have examined all variants in the imputed iCOGS dataset situated within 20kb of a panel 
of 179 DNA repair genes for association with PrCa or more aggressive phenotypic 
presentation. No novel risk variants were identified in our single SNP analysis, with only the 
previously reported signal at RAD51B on Chr14q24 genome-wide significant (Figure 1, 
Supplementary Table 3). Our analysis did not detect the previously reported signal at the 
RAD23B locus on Chr9q31, which was originally identified in the Chinese population and 
recently also confirmed in Europeans with the most significantly associated variant 
rs1771718 and the signal also an eQTL for RAD23B in normal prostate tissue in the TCGA 
dataset (Amin Al Olama et al, 2015; Xu et al, 2012). rs1771718 is located ~57kb downstream 
of RAD23B, which is the closest neighbouring gene but located in a distinct recombination 
block from these risk variants. Since no variant among the 509 within the gene centric 
region that we interrogated in this study showed substantial evidence for association 
(P≥2.94×10-3), it appears likely that risk at this locus is modulated through a nearby 
regulatory element controlling expression of the gene as opposed to intragenic causal 
functional variants (Supplementary figure 4).  
We conducted two gene level analyses in an attempt to identify whether there may be 
additional signals among the several loci that demonstrated suggestive but non-significant 
association peaks in our single SNP analysis, but for which no individual variant had achieved 
significance. SKAT-C tests for the combined effects of common and rare variants, whilst 
SKAT-O adaptively combines the burden test and SKAT test in an attempt to maximise 
power for rare variant association testing (Ionita-Laza et al, 2013; Lee et al, 2012). We 
identified a significant PrCa risk association after adjustment for multiple testing at the 
MSH5 gene at Chr6p21 using the SKAT-C test, implying that multiple common, or a 
combination of common and rare variants within this gene may contribute to PrCa risk. 
Although caution must be taken with respect to this finding until replicated and 
deconstructed, this evidence implicates MSH5 as a prospective PrCa susceptibility locus that 
warrants additional follow-up. MSH5 had previously been reported as a plausible candidate 
gene for the lung cancer risk locus at Chr6p21.33, for which the most strongly associated 
variant rs3117582 is intronic in BAT3, however is highly correlated to rs3131379 in intron 10 
of MSH5 (Kazma et al, 2012; Wang et al, 2008). A recent study examining cancer pleiotropy 
among DNA repair and DNA damage signalling pathway variants has also reported a highly 
significant association with lung cancer for rs3115672, a synonymous variant within MSH5, 
in addition to weaker associations with colon and serous ovarian cancers (pleiotropic OR 
1.18, 95% CI 1.12-1.24, P = 2.53×10-8) (Scarbrough et al, 2016). This variant was however 
non-significant for prostate cancer within their study of 14,160 PrCa cases and 12,724 
controls (OR 0.96, P = 0.21). Within our larger study (of which 2,614 cases and 2,679 
controls overlapped with those of Scarbrough et al.), in the single SNP analysis, rs3115672 
remained non-significant after adjustment for multiple testing (OR 0.94, 95% CI 0.90-0.98, P 
= 5.69×10-3). However, a number of other variants among the 312 within the MSH5 gene in 
our analysis were more strongly associated, the top individual variant of which was 
rs9281573 (OR 0.94, P = 4.01×10-5). StepAIC combined with SKAT leave one out selected two 
common and one rare variant as best explaining the SKAT-C association, all of which were 
among the top variants in the single SNP analysis. This implies that a combination of 
common and rare variants could potentially underpin this signal. 
We annotated these three variants for evidence of functionality using HaploReg v4.1 (Ward 
& Kellis, 2016); this annotation included chromatin state data for cell lines derived from 
multiple tissue types provided by the Roadmap Epigenomics Consortium (Roadmap 
Epigenomics et al, 2015), however no data for prostate tissue was available. rs61036903, 
which is intronic to MSH5, showed limited direct evidence for functionality itself. Both of the 
variants situated around the MSH5 promoter region, within VWA7, showed strong evidence 
for being located within enhancer elements that are active across a wide range of tissue 
types. In addition, expression data from the GTEx Consortium indicates that rs805825 is an 
eQTL for a number of genes from the MHC region (HLA-DRB1, HLA-DRB5, LY6G5C, DDAH2, 
LY6G6C, HSPA1B and C4B) (GTEx Consortium, 2015). These genes are clustered closely 
centromeric and telomeric of MSH5 and VWA7 within a gene dense locus; however no eQTL 
with MSH5 or VWA7 was observed for this variant. 
Whilst the MSH5 gene is routinely classified as a member of the mismatch repair (MMR) 
pathway along with all other homologues of MutS (Ji et al, 2012; Scarbrough et al, 2016; 
Wood et al, 2005), functional evidence to date provides limited support for a role in MMR 
for MSH5 itself. Instead, this gene has been implicated primarily in the processes of meiotic 
recombination, maintenance of chromosome integrity and DNA double strand break repair 
(Clark et al, 2013; Wu et al, 2013). RNA-seq data from GTEx Analysis Release V6 for 2712 
total samples across 51 normal human tissues (including 106 prostate tissue samples) 
demonstrates that MSH5 is expressed at broadly similar levels across a wide range of tissue 
types, including prostate (GTEx Consortium, 2015; accessed via. 
http://www.gtexportal.org/home/gene/MSH5). Data from TCGA further supports this 
expression profile across a range of normal tissues and also indicates that MSH5 is 
consistently overexpressed for almost all tumour types in comparison to their respective 
normal tissues. For TCGA prostate tissue, a median RSEM (log2) value of 8.08 was observed 
across 498 tumour samples compared with 6.85 from 52 normal samples 
(http://cancergenome.nih.gov/; accessed via. http://firebrowse.org/viewGene.html?gene 
=msh5). 
Taken together, these information demonstrate that although the MSH5 gene represents a 
strong biological candidate for the PrCa risk association that we have observed, additional 
functional follow up studies will be required to dissect the precise functional variants, genes, 
regulatory elements or processes that underpin this signal. 
It is worth noting that the gene level analyses in this study did not identify significant 
associations with any genes previously implicated in PrCa susceptibility. This was 
irrespective of whether the known risk mechanisms are believed to operate through 
multiple common, low penetrance variants (e.g. RAD51B; SKAT-O P = 0.05, SKAT-C P = 
2.76×10-3) or rare coding variants (e.g. BRCA2; SKAT-O P = 0.46, SKAT-C P = 0.15). In the case 
of BRCA2 and other genes in which rare, moderate penetrance, protein truncating PrCa 
susceptibility variants had previously been identified, this is likely to reflect the fact that 
even using the latest 1000 Genomes reference panel, rare variants expected to confer 
greater phenotypic consequences may remain absent from the reference panel and 
consequently unimputable. This is consistent with the poor representation of coding 
insertion and deletion variants within our dataset and would have rendered us 
underpowered to detect the effects of this class of variation in our analysis. Our 
observations do however imply that any additional contribution from common, lower 
penetrance variation at these genes may be minimal. This includes the rs11571833 
nonsense polymorphism in the terminal exon of BRCA2, which is a reported lung cancer 
susceptibility variant, but was not associated with PrCa in this study (OR 1.03, 95% CI 0.89-
1.19, P = 0.74) (Wang et al, 2014). It is perhaps more surprising that RAD51B did not achieve 
significance under the SKAT-C test, which considers the potential contribution towards 
association of both common and rare variants within a region, given that three independent 
associations have previously been identified at this locus (Amin Al Olama et al, 2015). 
However, a suggestive association was observed under this test, which may be an indication 
that the cumulative effect size of the independent low penetrance risk variants within this 
region were insufficient to be conclusively disambiguated through this methodology.  
Our pathway level analysis identified suggestive but non-significant associations for two 
pathways under the SKAT-O test; translesion synthesis and mismatch repair. Whilst this 
study did not therefore provide sufficient evidence to implicate genes within these 
pathways in PrCa susceptibility, given the inherently conservative nature of the Bonferroni 
correction with respect to type II error and the relatively low proportion of coding variants 
within our dataset, these observations may still justify further evaluation. In particular, since 
these suggestive associations were observed under the SKAT-O test that maximises power 
for rare variant association analyses and were not abrogated when the analyses were 
restricted only to coding variants, if substantiated, these nascent observations could be 
underpinned by direct effects of rare variants on the protein structure and function. 
Consequently, sequencing studies designed to comprehensively analyse the entire coding 
sequence of genes within the translesion synthesis and mismatch repair pathways could 
potentially yield further insight towards the mechanisms of susceptibility to developing 
PrCa. It is also worth noting that somatic mutations in translesion synthesis pathway genes, 
in particular the POLK gene, have been observed in prostate tumours previously (Makridakis 
& Reichardt, 2012; Yadav et al, 2015), whilst a rare germline nonsynonymous variant in the 
POLI gene has also been reported to predispose towards the occurrence of the TMPRSS2-
ERG fusion in PrCa patients (Luedeke et al, 2009). 
Increasing evidence suggests that moderate penetrance germline mutations within DNA 
repair genes also correlate with a more aggressive phenotypic presentation of PrCa and 
poorer prognosis (Castro et al, 2013; Cybulski et al, 2013; Leongamornlert et al, 2014; 
Robinson et al, 2015). This could in turn signify that DNA repair gene variants might exist 
that do not confer greater risk of developing PrCa per se, yet do modify the likelihood of 
developing more aggressive disease in individuals that develop PrCa due to other risk 
factors or exposures. We therefore also performed case-case analyses to further explore 
this hypothesis using two distinct phenotypic criteria. No significant or suggestive 
associations with aggressive disease were identified at the individual variant or gene levels 
under either definition, however suggestive non-significant associations with the 
Homologous Recombination/Fanconi Anemia pathway were observed. These analyses were 
however limited by relatively low sample numbers within each comparison group, which 
would have reduced our power to detect associations, particularly for rare and uncommon 
variants. We cannot therefore exclude the existence of additional DNA repair gene variants 
that promote increased PrCa aggressiveness rather than risk of the disease itself, however 
our data would suggest that any that exist are more likely to be rare than common. 
Overall, this study represents the most comprehensive interrogation of the role of DNA 
repair gene variants in PrCa susceptibility that we are aware of to date. We confirmed the 
presence of low penetrance susceptibility loci situated at the RAD51B locus and found 
evidence to implicate a novel gene, MSH5, in PrCa susceptibility. We also share preliminary 
observations that rare germline variation in genes within the translesion synthesis pathway, 
in particular variants within the coding sequence, could be worthy of further investigation as 
candidates for PrCa risk.  
The main limitations of our study relate to the challenges in imputing rare, potentially 
pathogenic variants to array genotype data from population based reference panels and in 
performing association tests on low frequency variants in a large multi-population study 
whilst controlling for population stratification. Therefore, additional sequencing studies 
would still be warranted to further explore the contribution of rare DNA repair gene variants 
to PrCa risk. In addition, incomplete availability of phenotypic data and the fact that the 
iCOGS study did not specifically select individuals with low or high grade disease may have 
reduced our ability to examine any potential influence of these variants on PrCa 
aggressiveness. Future studies, whether array or sequencing based, that specifically select 
patients from these cohorts for inclusion would facilitate investigation of this aspect; which 
might in turn help to enhance stratification of patients that require altered clinical 
management pathways. 
 
 
Methods  
Samples 
Samples for the iCOGS study were drawn from 25 studies participating in the PRACTICAL 
Consortium. The majority of studies were population-based or hospital-based case-control 
studies, or nested case-control studies; some studies selected samples by age or 
oversampled for cases with a family history of prostate cancer. Further information 
regarding the samples from the PRACTICAL Consortium included on the iCOGS array may be 
found within the original publication (Eeles et al, 2013). Analyses for DNA repair gene 
variants were restricted to samples of European ancestry. In total, genotype data for 21,780 
PrCa cases and 21,727 matched controls were available after quality control (QC).  
 
Genotyping and Imputation 
Genotyping was performed as part of the iCOGS project. This utilised a custom genotyping 
array designed in collaboration between the PRACTICAL (Prostate Cancer Association Group 
to Investigate Cancer Associated alterations in the Genome), BCAC (Breast Cancer 
Association Consortium), OCAC (Ovarian Cancer Association Consortium) and CIMBA 
(Consortium of Investigators of Modifiers of BRCA1/2) consortia. Detailed information about 
the design, genotyping and QC procedures for iCOGS can be found within the original 
publication (Eeles et al, 2013). In total 211,155 SNPs were genotyped on the iCOGS array, of 
which 3,510 were situated within our defined DNA repair gene regions. Imputation of the 
iCOGS PRACTICAL data was performed based on sequence data for 2504 samples from the 
1000 Genomes phase 3 reference panel (IMPUTE2 haplotype panel, October 2014 release; 
https://mathgen.stats.ox.ac.uk/impute/1000GP%20Phase%203%20haplotypes%206%20Oct
ober%202014.html) using SHAPEIT (v2 r778) and IMPUTE v2.3.1 in 588 chunks with a 
median size of 5Mb (Delaneau et al, 2013; Howie et al, 2009). Imputed data for non-
monomorphic variants with INFO scores ≥0.3 and MAF >0.001 were included in these 
analyses, which retained a total of 81,303 variants within the studied DNA repair gene 
regions. 
 
Gene/region selection 
We identified a total of 179 genes with a core function in DNA damage repair from the 
literature that intersected imputed iCOGS genotype data. We annotated DNA repair genes 
to a single primary DNA repair pathway according to previous curations (Kang et al, 2012; 
Wood et al, 2005). The genes analysed in this study represent the pathways Homologous 
recombination/Fanconi Anemia signalling network (HR/FA), base excision repair (BER), non-
homologous end joining (NHEJ), mismatch repair (MMR), nucleotide excision repair (NER), 
translesion synthesis (TLS), ATM signalling (ATM), RECQ helicase family (RECQ), crosslink 
repair (XLR), and other miscellaneous DNA repair genes with functions including 
endonuclease/exonuclease activity and modification of chromatin structure (Other). Gene 
coordinates were assigned according to GENCODE release 19 (GRCh37.p13), with a 20kb 
flank added to define the study region for each gene, in order to focus primarily on 
capturing gene and promoter centric variation over that within regulatory elements which 
can be located at variable and potentially relatively large distances from the gene itself. 
Variants were annotated using wANNOVAR to facilitate designation as coding, intronic, UTR, 
splice and intergenic (Chang & Wang, 2012; Wang et al, 2010). A full list of the DNA repair 
genes analysed in this study, their pathway annotations, region co-ordinates and the 
number of typed and imputed variants available is included in Supplementary Table 1.  
 
Statistical analyses 
Analyses were adjusted for study groups and the first eight principal components. For single 
SNP analyses the genome-wide significance threshold was employed (P<5×10-8), whereas 
for gene and pathway level tests the Bonferroni correction was used to determine multiple 
testing adjusted significance thresholds (Gene P<2.7×10-4, Pathway P<5.56×10-3).  
All analyses were carried out using R. For single SNP analyses, per allele odds ratios were 
estimated using logistic regression. SKAT tests were performed using the SKAT package for R 
(http://CRAN.R-project.org/package=SKAT). We used the SKAT-O and SKAT-C tests for 
optimal analyses of the combined effect of multiple rare variants and common and rare 
variants respectively (Ionita-Laza et al, 2013; Lee et al, 2012; Wu et al, 2011). Tests were 
conducted using default parameters and a common/rare cut-off threshold of MAF = 0.01 for 
the SKAT-C test. StepAIC and SKAT leave one out were used to further interrogate the 
significant SKAT signal at the MSH5 gene for the individual variants that best described the 
signal. 
Analyses for low grade versus high grade PrCa were carried out based on two clinical 
criteria. For stringent comparison of non-aggressive and aggressive PrCa, we defined NCCN 
stage 1 patients as non-aggressive PrCa and individuals with metastatic disease (M+) or 
nodal spread (N+) as aggressive (395 NCCN1 vs. 1391 M+/N+); whilst to enhance the sample 
panel available for this analysis we also compared patients with Gleason Stage ≤6 against 
those with Gleason Stage ≥8 disease (9626 GS≤6 vs 2776 GS≥8). 
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